Shares in Intersect ENT (NSDQ:XENT) fell slightly today even though the drug-device company met expectations on Wall Street with its 4th quarter results.
The Menlo Park, Calif.-based company pared losses to -$4.8 million, or -17¢ per share, on sales of $24.2 million for the 3 months ended Dec. 31, for bottom-line growth of 15.8% on sales growth of 28.7% compared with the same period last year.
Adjusted to exclude 1-time items, earnings per share were -17¢, ahead of consensus on The Street, where analysts were looking for sales of $23.1 million.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT reels in losses, beats revenue estimates for Q4 appeared first on MassDevice.
from MassDevice http://ift.tt/2mdONiB
Cap comentari:
Publica un comentari a l'entrada